ScholarIQanswers from OpenAlex
Comprehensive Blood & Cancer Center
InstitutionResearch output, impact & collaborations
Comprehensive Blood & Cancer Center is a institution indexed in ScholarIQ from OpenAlex.
What is known about Comprehensive Blood & Cancer Center?
ScholarIQrecord summary
Comprehensive Blood & Cancer Center is a research organisation in Bakersfield, US. OpenAlex records 1,019 works and 227,877 citations for it. 222 researchers list it as their most recent affiliation.
How many works does Comprehensive Blood & Cancer Center have?
ScholarIQindexed works
Comprehensive Blood & Cancer Center has 1,019 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Comprehensive Blood & Cancer Center have?
ScholarIQcitation count
Comprehensive Blood & Cancer Center has 227,877 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Comprehensive Blood & Cancer Center?
ScholarIQresearcher count
Comprehensive Blood & Cancer Center has 222 researchers in the ScholarIQ index.
What is the average h-index at Comprehensive Blood & Cancer Center?
ScholarIQavg h-index
Comprehensive Blood & Cancer Center has an average h-index of 100 in OpenAlex.
What is the ROR of Comprehensive Blood & Cancer Center?
ScholarIQror
The ROR for Comprehensive Blood & Cancer Center is on the source record.
What is the OpenAlex record for Comprehensive Blood & Cancer Center?
ScholarIQopenalex
The OpenAlex for Comprehensive Blood & Cancer Center is on the source record.
Who are the most-cited researchers behind Comprehensive Blood & Cancer Center?
ScholarIQtop researchers by citations
What are the most-cited papers on Comprehensive Blood & Cancer Center?
ScholarIQmost cited works
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M. Gadgeel, Toyoaki Hida, Dariusz M. Kowalski, Manuel Cobo, Diego Cortinovis, Joseph W. Leach, Jonathan Polikoff, Carlos H. Barrios, Fairooz F. Kabbinavar, Osvaldo Arén Frontera, Filippo de Marinis, Hande Turna, Jong-Seok Lee, Marcus Ballinger, Marcin Kowanetz, Pei He, Daniel S. Chen, Alan Sandler, David R. Gandara
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Giorgio V. Scagliotti, Purvish Parikh, Joachim von Pawel, Bonne Biesma, Johan Vansteenkiste, Christian Manegold, Piotr Serwatowski, U. Gatzemeier, Raghunadharao Digumarti, Mauro Zukin, Jin S. Lee, Anders Mellemgaard, Keunchil Park, Shehkar Patil, Janusz Rolski, Tuncay Göksel, Filippo de Marinis, Lorinda Simms, Katherine P. Sugarman, David R. Gandara
Vinorelbine plus Cisplatin vs. Observation in Resected Non–Small-Cell Lung Cancer
Timothy Winton, Robert B. Livingston, David C. Johnson, James R. Rigas, Michael Johnston, Charles Butts, Yvon Cormier, Glenwood Goss, Richard Inculet, Eric Vallières, Willard A. Fry, Drew Bethune, Joseph Ayoub, Keyue Ding, Lesley Seymour, Barbara Graham, Ming‐Sound Tsao, David R. Gandara, Kenneth A. Kesler, Todd L. Demmy, Frances A. Shepherd
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial
Kathy S. Albain, Ruth Swann, Valerie W. Rusch, Andrew T. Turrisi, Frances A. Shepherd, Colum J Smith, Yuhchyau Chen, Robert B. Livingston, Richard H. Feins, David R. Gandara, Willard A. Fry, Gail Darling, David H. Johnson, Mark R. Green, Robert C. Miller, Joanne Ley, W. Sause, James D. Cox
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
Naiyer A. Rizvi, Julien Mazières, David Planchard, Thomas E. Stinchcombe, Grace K. Dy, Scott Antonia, Leora Horn, H. Léna, Elisa Minenza, B. Mennecier, Gregory A. Otterson, Luis T. Campos, David R. Gandara, Benjamin Levy, Suresh Nair, Gérard Zalcman, Jürgen Wolf, Pierre‐Jean Souquet, Editta Baldini, Federico Cappuzzo, C. Chouaïd, Afshin Dowlati, Rachel E. Sanborn, Ariel López-Chávez, Christian Grohé, Rudolf M. Huber, Christopher Harbison, Christine Baudelet, Brian Lestini, Suresh S. Ramalingam
How much of the research on Comprehensive Blood & Cancer Center is open access?
ScholarIQopen access share
67%OPEN ACCESS